Pa Ogasiti 24, 2022, bungwe la US Food and Drug Administration (FDA) linavomereza ibrutinib kuti igwiritsidwe ntchito pochiza odwala azaka zopitilira chaka chimodzi omwe ali ndi matenda osachiritsika a graft-versus-host (cGVHD) omwe akulandira chithandizo chamankhwala cha mzere umodzi kapena zingapo. Chizindikiro chovomerezeka makamaka ndi cha ana, omwe ali ndi chiwerengero chonse cha kuyankha cha 60% pa sabata la 25, ndipo mankhwala omwe amaperekedwa akuphatikizapo makapisozi, mapiritsi ndi mankhwala operekedwa pakamwa.
Ibrutinib, choletsa cha BTK chomwe chinapangidwa pamodzi ndi Pharmacyclics/Johnson & Johnson, ndi choletsa cha kinase chomwe chinavomerezedwa kale kuti chichiritse khansa ya m'magazi yosatha komanso khansa ya m'magazi ndi matenda ena.
Suntech imayang'ana kwambiri pakupanga ndi kupanga mankhwala osakaniza ndi ma API pogwiritsa ntchito ukadaulo wobiriwira. Pakadali pano, kampani yathu yapanga zinthu zitatu zapakati za ibrutinib kuphatikiza C AS: 143900-44-1, C AS: 330792-70-6, C AS: 330786-24-8, zomwe zonse zagulitsidwa m'mafakitale opanga GMP. Pakati pawo, C AS: 143900-44-1 imapangidwa ndi ukadaulo wa mankhwala-enzyme, womwe uli ndi ubwino woteteza chilengedwe chobiriwira, mtengo wotsika komanso khalidwe lapamwamba. Takulandirani kuti mukambirane ndikugwirizana!
Nthawi yotumizira: Novembala-04-2022